Take Solutions Limited (TAKE) Fair Value & Analysis
Healthcare · IN · Market cap ₹3.3B
Fair value as of: Aug 13, 2026
From 10 valuation models · updated 4 days ago
Share price +23.0% over the past month.
A solid business, but screening 64% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹15.77). The favourable scenario is already priced in.
- The model range is unusually wide (₹5.10 to ₹15.77). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹6.69 – ₹71.70 · fair‑value band ₹5.10 – ₹15.77 · the ₹23.43 price screens above the ₹8.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Take Solutions Limited (TAKE) currently trades at ₹23.43, while our model-based Fair Value estimate is ₹8.47, implying the stock looks roughly 63.9% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Take Solutions Limited generated revenue of ₹542M at a net margin of 20.0%. Revenue declined 82.9% year over year. It earns a return on equity of 16.5%. The balance sheet holds a net cash position of ₹2.8M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹5.10 (bear case) to ₹15.77 (bull case); at ₹23.43, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high and 164% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -64%, TAKE screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Multiples (₹12.61) versus Dividend Discount (₹0.0300). Highest evidence: Residual Income (76).
Notify me when TAKE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise.
Full company description
TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access to billing insight through cloud adoption. In addition, the company offers payer-provider digital solution, which includes personalized medicine, wellness, and patient engagement; and medical device solution, such as technological transformation with chip level programming, DICOM devices, wearables, PROM, nano devices, and miOTs. TAKE Solutions Limited was incorporated in 2000 and is based in Chennai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Take Solutions Limited reported revenue of ₹542M in FY2026 versus ₹6.5B in FY2022, a compound −46.3%/yr. Reported net income was ₹108M in FY2026.
TAKE screens 64% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Take Solutions Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Take Solutions Limited (TAKE) overvalued or undervalued?
What is the fair value of TAKE?
What is the quality score of TAKE?
What is the revenue of Take Solutions Limited (TAKE)?
What is the net profit margin of TAKE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Take Solutions Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.